Acta Cardiologica Sinica最新文献_第4页

Beyond Respiratory Failure: Recognizing the Reversibility of Dasatinib-Induced Pulmonary Arterial Hypertension and Concurrent Hyperthyroidism. 超越呼吸衰竭：认识达沙替尼诱导的肺动脉高压和并发甲状腺功能亢进的可逆性。

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-07-01 DOI: 10.6515/ACS.202607_42(4).20260506B

Ly T M Nguyen, Hieu L Nguyen, Thanh T L Nguyen, Anh L Nguyen

引用次数: 0

Intermittent Fever in Eisenmenger Syndrome with Pulmonary Artery Thrombosis. 艾森曼格综合征并发肺动脉血栓的间歇性发热。

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-07-01 DOI: 10.6515/ACS.202607_42(4).20260506A

Yung-Tang Tsao, Wan-Jing Ho, Cze-Ci Chan, Chieh-Yu Chang

引用次数: 0

Familial Hereditary Hemorrhagic Telangiectasia with Stroke in Two Generations: Diagnostic Delay and the Role of Patient-Specific Three-Dimensional-Printed Models in Endovascular Planning. 两代中风家族遗传性出血性毛细血管扩张：诊断延迟和患者特异性三维打印模型在血管内规划中的作用。

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-07-01 DOI: 10.6515/ACS.202607_42(4).20260411A

Ke-Yun Chao, Chao-Yu Chen, Yi-Zhen Chu, Hīng-Ka Lîm, Shu-Chi Mu, Yu-Hsuan Chien

引用次数: 0

Clinical Outcomes of Intravascular Lithotripsy for Severely Calcified Coronary Lesions: A Single-Center Study. 血管内碎石治疗严重钙化冠状动脉病变的临床结果：单中心研究

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-07-01 DOI: 10.6515/ACS.202607_42(4).20251124E

Chien-Po Huang, Tien-Ping Tsao, Hao-Neng Fu, Hsin-I Teng, Yu-Cheng Kao, Hsu-Lung Jen, Wei-Hsian Yin

{"title":"Clinical Outcomes of Intravascular Lithotripsy for Severely Calcified Coronary Lesions: A Single-Center Study.","authors":"Chien-Po Huang, Tien-Ping Tsao, Hao-Neng Fu, Hsin-I Teng, Yu-Cheng Kao, Hsu-Lung Jen, Wei-Hsian Yin","doi":"10.6515/ACS.202607_42(4).20251124E","DOIUrl":"10.6515/ACS.202607_42(4).20251124E","url":null,"abstract":"Background: Intravascular lithotripsy (IVL) is an emerging calcium modification technique designed to optimize stent expansion in patients with severely calcified coronary artery disease. While clinical trials support its efficacy, real-world data from Asia remain limited.Objectives: To evaluate the procedural success, safety, and 1-year clinical outcomes of IVL in a single-center Taiwanese cohort.Methods: This retrospective single-center cohort study enrolled patients undergoing IVL for complex calcified coronary lesions between November 2022 and October 2024.Results: The 1-year MACE rate was 13.6% (raw proportion), driven by cardiac death (1.5%), myocardial infarction (4.5%), ischemia-driven target vessel revascularization (7.6%), and prior in-stent restenosis requiring repeat revascularization (3.0%). The Kaplan-Meier-estimated 1-year cumulative incidence of MACEs was 14.9%. Subgroup analyses showed significantly higher MACE and revascularization rates in patients with end-stage renal disease (ESRD) (p = 0.004, 0.012) and in non-bifurcation lesions (p = 0.014). Multivariable analysis identified ESRD as an independent predictor of MACEs (hazard ratio [HR]: 5.790, p = 0.004) and revascularization (HR: 7.233, p = 0.015); stent under-expansion was also independently associated with revascularization (HR: 7.030, p = 0.010). These findings highlight the clinical performance of IVL and key predictors of adverse outcomes.Conclusions: IVL appears to be safe and effective for managing complex calcified coronary lesions. Outcomes in this study were influenced by renal dysfunction and stent expansion.","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"42 4","pages":"551-561"},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13409420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148617926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-Density Lipoprotein Treatment Effectively Protected the Endothelial Cells, Mitochondria and Myocardium Against Oxidized Low-Density Lipoprotein Damage. 高密度脂蛋白治疗可有效保护内皮细胞、线粒体和心肌免受氧化性低密度脂蛋白损伤。

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-07-01 DOI: 10.6515/ACS.202607_42(4).20251124C

Han-Tan Chai, Yi-Ling Chen, Chi-Ruei Huang, Pei-Hsun Sung, John Y Chiang, Hon-Kan Yip

{"title":"High-Density Lipoprotein Treatment Effectively Protected the Endothelial Cells, Mitochondria and Myocardium Against Oxidized Low-Density Lipoprotein Damage.","authors":"Han-Tan Chai, Yi-Ling Chen, Chi-Ruei Huang, Pei-Hsun Sung, John Y Chiang, Hon-Kan Yip","doi":"10.6515/ACS.202607_42(4).20251124C","DOIUrl":"10.6515/ACS.202607_42(4).20251124C","url":null,"abstract":"Background: This study evaluated whether high-density lipoprotein (HDL) treatment, shown to preserve endothelial cell integrity, could protect the left ventricular ejection fraction (LVEF) in rats from ischemia-reperfusion (IR) injury.Methods: Human umbilical vein endothelial cells (HUVECs) were assigned to six groups: G1 (HUVECs alone); G2 (+healthy-derived oxidized LDL [ox-LDLH]); G3 (+ox-LDLH + healthy-derived HDL [HDLH]); G4 (+acute-coronary-syndrome patient-derived ox-LDL [ox-LDLP]); G5 (+ox-LDLP+ HDLH); and G6 (+ox-LDLP + patient-derived HDL [HDLP]). Male Sprague-Dawley rats (n = 54) were divided equally into Group 1 (subcutaneous control), Group 2 (IR only), and Groups 3-6 (IR plus ox-LDLH, HDLH, ox-LDLP, or HDLP, respectively, implanted into the left ventricular myocardium 3 h after IR).Results: In vitro, protein and cellular markers of apoptosis, oxidative stress, mitochondrial damage, and MAPK-family signaling were lowest in G1, highest in G4, and significantly lower in G3 than in G2, G5, and G6 (all p < 0.0001); antioxidants and angiogenesis showed the opposite pattern. By day 28, LVEF and LV fractional shortening were highest in Group 1, lowest in Group 5, higher in Group 4 than in Groups 2, 3, and 6, and higher in Group 6 than in Groups 2 and 3 (all p < 0.0001). Inflammation, MAPK cascades, oxidative stress, mitochondrial damage, and LV infarct/fibrotic areas followed the inverse pattern, while antioxidants paralleled LVEF.Conclusions: HDLH protected heart function against IR-induced myocardial damage by inhibiting inflammation and oxidative stress and modulating MAPK-family signaling.","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"42 4","pages":"562-582"},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13409424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148617933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Delayed Presentation of Suicide LV: Post-AVR LVOT Obstruction Cured by Alcohol Septal Ablation. 延迟出现自杀性左室：酒精室间隔消融治疗avr后左室梗阻。

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-07-01 DOI: 10.6515/ACS.202607_42(4).20260601A

Wei-Cheng Liao, Jung-Cheng Hsu, Yen-Wen Wu, Jer-Shen Chen

引用次数: 0

A Streamlined Technique for Transseptal Mitral Valve-in-Valve Replacement. 经鼻中隔二尖瓣置换术的流线型技术。

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-07-01 DOI: 10.6515/ACS.202607_42(4).20260601B

Chun-Chin Chang, Ching-Wei Lee, Yi-Lin Tsai, Su-Chan Chen, Tai-Wei Chen, Chiao-Po Hsu, Shih-Hsien Sung

引用次数: 0

PCSK9 Inhibitor Attenuates Platelet TLR4 in ACS and TLR4 Blockers Prevent PCSK9-Mediated Platelet Activation. PCSK9抑制剂可减弱ACS患者血小板TLR4，而TLR4阻滞剂可阻止PCSK9介导的血小板活化。

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-07-01 DOI: 10.6515/ACS.202607_42(4).20260126A

Lingshan Qi, Meng Yuan, Xing Liu, Tong Liu, Yue Zhang, Kangyin Chen

{"title":"PCSK9 Inhibitor Attenuates Platelet TLR4 in ACS and TLR4 Blockers Prevent PCSK9-Mediated Platelet Activation.","authors":"Lingshan Qi, Meng Yuan, Xing Liu, Tong Liu, Yue Zhang, Kangyin Chen","doi":"10.6515/ACS.202607_42(4).20260126A","DOIUrl":"10.6515/ACS.202607_42(4).20260126A","url":null,"abstract":"Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates platelet activation through multiple signaling pathways. This study aimed to determine whether PCSK9 modulates platelet activation via Toll-like receptor 4 (TLR4).Methods: A total of 120 patients with acute coronary syndrome (ACS) were divided into a control group and an experimental group receiving subcutaneous evolocumab. Platelet surface TLR4 was quantified by flow cytometry. Platelet-rich plasma from healthy volunteers (n = 5) was incubated with normal saline, PCSK9, PCSK9 + evolocumab, or PCSK9 + the TLR4 inhibitor resatorvid (TAK-242). Platelets were then stimulated with adenosine diphosphate, and aggregation was measured. Plasma thromboxane A2 (TXA2) was measured by ELISA. Megakaryoblastic leukemia cells (MEG-01) were co-incubated with PCSK9 and stained for TLR4 and PCSK9 by immunofluorescence.Results: PCSK9 significantly enhanced platelet aggregation and TXA2 release in vitro; both effects were abolished by evolocumab and TAK-242. In ACS patients, evolocumab treatment reduced platelet surface TLR4 expression and decreased plasma TXA2 levels. Dual immunofluorescence staining demonstrated co-localization of TLR4 and PCSK9 in MEG-01 cells.Conclusions: This study provides the first evidence that PCSK9 inhibitors downregulate platelet TLR4 expression in ACS patients. The pro-aggregatory effects of PCSK9 on platelets were counteracted by TLR4 inhibition, indicating a mechanistic link between PCSK9 and TLR4 signaling in platelet activation. Co-localization of TLR4 and PCSK9 in MEG-01 cells supports a potential interaction between the two proteins.","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"42 4","pages":"596-605"},"PeriodicalIF":1.9,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13409463/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148617959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Dawn of a New Era in Hypertrophic Cardiomyopathy. 肥厚性心肌病新时代的曙光。

IF 1.8 4区医学

Acta Cardiologica Sinica Pub Date : 2026-05-01 DOI: 10.6515/ACS.202605_42(3).20260420A

Wen-Chung Yu

引用次数: 0

Unruptured Sinus of Valsalva Aneurysms and Severe Aortic Valve Regurgitation Combined with Multiple Intracranial and Iliac Artery Aneurysms. 未破裂的Valsalva动脉瘤和严重主动脉瓣返流合并多发性颅内和髂动脉动脉瘤。

IF 1.9 4区医学

Acta Cardiologica Sinica Pub Date : 2026-05-01 DOI: 10.6515/ACS.202605_42(3).20260218A

Zongyue Li, Bin Hu, Wenlong Zhang, Shouji Zhang

引用次数: 0